Michael Naughton

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Shunqiang Li, Dong Shen, Jieya Shao et al. · Cell Reports · 2013 · 625 citations · Full text

Medicine, Genetics, Oncology +14

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo et al. · Clinical Cancer Research · 2017 · 376 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A molecular-imprint nanosensor for ultrasensitive detection of proteins

Dong Cai, Lu Ren, Huaizhou Zhao et al. · Nature Nanotechnology · 2010 · 358 citations · Full text

Engineering, Biomedical Engineering, Biotechnology +13

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski et al. · Clinical Cancer Research · 2009 · 303 citations · Full text

Medicine, Oncology, Pharmacology +13

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

Rebecca Aft, Michael Naughton, Kathryn Trinkaus et al. · The Lancet Oncology · 2010 · 273 citations · Full text

Medicine, Oncology, Pharmacology +10